0 82

Cited 3 times in

Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study

 Min‐Geol Lee  ;  Yu‐Huei Huang  ;  Joo‐Heung Lee  ;  Seung‐Chul Lee  ;  Tae‐Gyun Kim  ;  Derrick Chen‐Wee Aw  ;  Weibin Bao  ;  Cathleen Michelle A. Dee  ;  Adriana Guana  ;  Tsen‐Fang Tsai 
 JOURNAL OF DERMATOLOGY, Vol.46(9) : 752-758, 2019 
Journal Title
Issue Date
Adult ; Aged ; Antibodies, Monoclonal/administration & dosage* ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal, Humanized ; Asian Continental Ancestry Group ; Dermatologic Agents/administration & dosage* ; Dermatologic Agents/adverse effects ; Double-Blind Method ; Female ; Humans ; Injections, Subcutaneous ; Male ; Middle Aged ; Psoriasis/diagnosis ; Psoriasis/drug therapy* ; Psoriasis/pathology ; Severity of Illness Index ; Skin/drug effects ; Skin/pathology ; Time Factors ; Ustekinumab/administration & dosage* ; Ustekinumab/adverse effects
Asian ; efficacy ; plaque psoriasis ; secukinumab ; ustekinumab
The 52-week results from the CLEAR (NCT02074982) study showed high and superior efficacy of secukinumab versus ustekinumab in clearing skin and improving patient-reported outcomes, with comparable safety profile in subjects with moderate to severe psoriasis. Here, we analyzed the efficacy and safety of secukinumab in Asian subjects from the CLEAR study. In this double-blind, phase IIIb study, eligible subjects with moderate to severe plaque psoriasis were randomized (1:1) to receive s.c. injection of secukinumab 300 mg or ustekinumab as per label. Of 62 subjects included in Asian subanalyses, 23 were randomized to secukinumab and 39 to ustekinumab. A significantly higher proportion of subjects achieved 90% or more improvement in Psoriasis Area and Severity Index (PASI 90) with secukinumab versus ustekinumab at week 16 (78.3% vs 35.9%, P = 0.0010) and at week 52 (60.9% vs 33.3%, P = 0.0196). Similarly, a higher proportion of subjects achieved PASI 100 with secukinumab versus ustekinumab at week 16 (43.5% vs 10.3%, P = 0.0029) and at week 52 (30.4% vs 12.8%, P = 0.0704). The median time to achieve 50% improvement in baseline PASI was 2.8 weeks in the secukinumab group versus 6.3 weeks in the ustekinumab group. The safety profile of secukinumab was in line with the known profile and no deaths occurred. Overall, 95.7% and 84.6% of subjects remained on secukinumab and ustekinumab, respectively. Similar to the core study, secukinumab showed sustained and superior efficacy with faster response versus ustekinumab, and no new or unexpected safety concerns were identified, in Asian subjects with moderate to severe plaque psoriasis.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Microbiology (미생물학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Dermatology (피부과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Tae-Gyun(김태균) ORCID logo https://orcid.org/0000-0002-2116-4579
Lee, Min Geol(이민걸) ORCID logo https://orcid.org/0000-0001-7040-5335
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.